Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

edwardport

03/31/20 7:52 PM

Post #5

research indicates strong company here

AnotherInvestor

08/31/18 12:53 PM

Post #4

Why is it up today, in volume and price?

r clarke

12/11/17 7:29 PM

Post #3

Re: #2: @AD2000 - Up and up?

This seems to be a bit oversold.
Seems to have found support and is moving up a bit.

AD2000

05/15/17 9:32 PM

Post #2

Up and up?

stocktrademan

04/16/17 4:04 PM

Post #1

RARX bullish 22.82

bull flag

normal chart

log chart

Ra Pharmaceuticals, Inc. (RARX)

Followers	0	Posters	5
Posts (Today)	0	Posts (Total)	5
Created	04/16/17	Type	Free
Moderators

Ra Pharmaceuticals, Inc. 87 Cambridge Park Drive Cambridge Cambridge, MA 02140 United States 617-401-4060 http://www.rapharma.com Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis (rMG) and lupus nephritis (LP). The company's preclinical testing products include Factor D inhibition for age-related macular degeneration and geographic atrophy, as well as for Orphan renal dense deposit and C3 glomerulonephritis; Oral C5 inhibitor for PNH, rMG, LN, and central nervous system (CNS) diseases; and C1s inhibition for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.